Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL C
Go back to Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL C| (NASDAQ: AVIR) | Delayed: 4.98 +0.20 (4.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.78 | 52 Week High | $2.00 | |||
| Open | $4.78 | 52 Week Low | $1.15 | |||
| Day High | $5.04 | P/E | N/A | |||
| Day Low | $4.78 | EPS | $0.00 | |||
| Volume | 415,177 | |||||
